Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elegant Research and Development LLC

Neither a doctor nor a teaching hospital

Research payments

$2,467,941

80 payments

Through program year 2025, Elegant Research and Development LLC is reported as receiving $2,467,941 in research payments, across 80 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $384,991 9
2024 Research $296,898 6
2023 Research $212,757 17
2022 Research $371,416 7
2021 Research $451,858 20
2020 Research $424,202 12
2019 Research $325,819 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,484,036 19 payments
  2. Novartis Pharmaceuticals Corporation $635,842 15 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $143,028 28 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $104,170 4 payments
  5. Avanir Pharmaceuticals, Inc. $82,198 11 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $14,767 2 payments
  7. Regeneron Pharmaceuticals, Inc. $3,900 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease Ad Geras US $675,127 10 payments
  2. Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (Triumph) $554,334 6 payments
  3. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $272,771 3 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $222,565 1 payment
  5. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $216,347 5 payments
  6. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $100,724 4 payments
  7. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $64,245 15 payments
  8. BAY94-8862 LCM HFmr/pEF (EF 40%) $57,873 11 payments
  9. HF Opt $54,090 2 payments
  10. 15-Avp-786-303 $49,568 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record